NCT02189720 2025-03-26
EAP-001
Catalyst Pharmaceuticals, Inc.
Approved for marketing
Clinical Trials
11 trialsNCT03579966 2024-05-07
Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)
Catalyst Pharmaceuticals, Inc.
Phase 3 Terminated
NCT03304054 2024-03-12
Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
Catalyst Pharmaceuticals, Inc.
Phase 3 Completed
NCT05919407 2023-06-26
IMPACT-MG
Leiden University Medical Center
Phase 3 Unknown
NCT00872950 2022-04-11
LEMS
Lahey Clinic
Approved for marketing
NCT02012933 2019-12-11
3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)
Oregon Health and Science University
No longer available
NCT00704925 2019-10-30
Treatment of Lambert-Eaton Syndrome With 3,4 DAP
University of California, Davis
No longer available
NCT01377922 2018-01-04
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
Catalyst Pharmaceuticals, Inc.
Phase 3 Completed
NCT01511978 2017-07-11
DAPPER
Jacobus Pharmaceutical
Phase 2 Completed
NCT00004832 2015-03-25
Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome
FDA Office of Orphan Products Development
Phase NA Completed
NCT01378546 2013-07-18
Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP
Columbia University
No longer available